Cardiovascular HealthVisceral fat, which surrounds organs deep in the abdomen, was more strongly associated with type 2 diabetes risk than body mass index (BMI) in a study of 36,831 UK Biobank participants published July 15, 2026, in the International Journal of Obesity. A second study, published online July 26 in Adipocyte, compared visceral and subcutaneous fat […]
Read the Full Bite →
Clinical Research & TrialsPeople taking glucagon-like peptide-1 (GLP-1) receptor agonists reported nail detachment and discoloration more often than nonusers with obesity or type 2 diabetes in a multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. The cross-sectional analysis compared 575 GLP-1 users with 1,329 nonusers across four countries, but it cannot establish […]
Read the Full Bite →
Cardiovascular HealthA European Heart Journal meta-analysis of 87 randomized trials found that higher whole-grain intake modestly improved LDL cholesterol, fasting glucose, blood pressure and other cardiometabolic risk factors.
Read the Full Bite →
Clinical Research & TrialsIn the RESET for Remission randomized trial, 54% of younger adults with obesity and early-onset type 2 diabetes reached remission after a low-energy diet plus structured exercise, compared with 4% receiving usual care.
Read the Full Bite →
Clinical Research & TrialsCBL-514 reduced abdominal subcutaneous fat in randomized phase 2 trials and showed an early visceral-fat signal, but it is not yet a proven obesity or weight-loss treatment.
Read the Full Bite →
Clinical Research & TrialsA two-year randomized trial found that diet drinks and water produced equivalent long-term weight-loss outcomes during a behavioral weight-management program.
Read the Full Bite →
Clinical Research & TrialsRetatrutide has already attracted attention for the amount of weight loss seen in obesity trials. New Phase 3 results now answer a different question: how well can the experimental drug address obesity and high blood sugar at the same time in people with type 2 diabetes? In the TRIUMPH-2 trial, adults with type 2 diabetes […]
Read the Full Bite →
Cancer & OncologyObesity has long been linked to cancers of the colon, kidney, liver, endometrium and several other organs. A major 2026 analysis suggests that the list may be broader than the 13 cancer types commonly highlighted in public-health guidance. Researchers from the National Cancer Institute, Imperial College London and Johns Hopkins University combined evidence from 226 […]
Read the Full Bite →
Clinical Research & TrialsGLP-1 drugs have been linked to hair loss, but the absolute risk is small and rapid weight loss may be part of the explanation. Here is what the evidence shows.
Read the Full Bite →
Cell & Molecular BiologyGLP-1 links the gut, pancreas, stomach, and brain. Here is how the pathway controls blood sugar, appetite, gastric emptying, and weight.
Read the Full Bite →
Clinical Research & TrialsOral and injectable Wegovy use the same drug but differ in dosing, absorption, and convenience. Here is how the evidence compares for obesity treatment.
Read the Full Bite →
Aging & LongevityObesity is linked to changes in brain structure, cognition, and dementia risk, especially in midlife. Here is what recent research shows and what remains uncertain.
Read the Full Bite →
Clinical Research & TrialsSemaglutide and tirzepatide reduce lean mass during weight loss, but mostly reduce fat. Here is what DXA studies show about muscle, sarcopenia, and resistance training.
Read the Full Bite →
Diabetes & MetabolismSemaglutide and tirzepatide withdrawal trials show substantial weight regain after treatment stops. Here is what the evidence says and what it does not.
Read the Full Bite →
Clinical Research & TrialsIn the SURMOUNT-5 head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide at 72 weeks, but the comparison has important limits.
Read the Full Bite →
Diabetes & MetabolismNausea and other gastrointestinal symptoms are common with GLP-1-based medicines, while pancreatitis, gallbladder disease, dehydration, and other serious risks are less frequent.
Read the Full Bite →
Diabetes & MetabolismGIP and GLP-1 both increase meal-stimulated insulin secretion, but their biology differs. Tirzepatide activates both receptors, creating a distinct dual-incretin drug profile.
Read the Full Bite →
Aging & LongevityIn a Nature study, semaglutide extended median lifespan by 92 days in older female mice and reproduced many effects of calorie restriction.
Read the Full Bite →
Diabetes & MetabolismWorking out releases tiny cellular packages that may protect against type 2 diabetes.
Read the Full Bite →